Osteoporosis is a common disease of older adults and is a major public health problem
worldwide. As the population ages, the incidence of osteoporosis and resulting osteoporotic
fractures is increasing. Although osteoporosis is more common in women than in men,
the incidence in men is increasing. The disability, mortality, and cost of hip and
vertebral fractures are substantial in the rapidly growing, aging population so that
prevention and treatment of osteoporosis is a major public health concern. This article
reviews the impact of osteoporosis and provides an evidence-based approach toward
preventing and treating osteoporosis and its complications.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Clinics in Geriatric MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Lifetime risks of hip, colles', or vertebral fracture and coronary heart disease among white postmenopausal women.Arch Intern Med. 1989; 149: 2445-2448
- The diagnosis of osteoporosis.J Bone Miner Res. 1994; 9: 1137-1141
- Prevalence of low femoral bone density in older U.S. Women from NHANES III.J Bone Miner Res. 1995; 10: 796-802
- Risk of hip fracture according to the world health organization criteria for osteopenia and osteoporosis.Bone. 2000; 27: 585-590
- Bone density at various sites for prediction of hip fractures. The Study of Osteoporotic Fractures research group.Lancet. 1993; 341: 72-75
- Hip fracture outcomes in people age 50 and over. US Congress, Office of Technology Assessment, OTA-BP-H-120, Washington (DC)1994
- Hip fracture incidence among the old and very old: a population-based study of 745,435 cases.Am J Public Health. 1990; 80: 871-873
- Hip fractures: a worldwide problem today and tomorrow.Bone. 1993; 14: S1-S8
- Hip fractures in the elderly: a world-wide projection.Osteoporos Int. 1992; 2: 285-289
- Epidemiology of hip fractures.Bone. 1996; 18: 57S-63S
- The aging of America. Impact on health care costs.JAMA. 1990; 263: 2335-2340
- Epidemiology of osteoporosis.Osteoporos Int. 1999; 9: S2-S8
- Epidemiology of osteoporosis in the United States of America.Osteoporos Int. 1997; 7: S68-S72
- Vertebral fracture epidemiology.Bone. 1996; 18: 179S-183S
- The prevalence of vertebral deformity in european men and women: The European vertebral osteoporosis study.J Bone Miner Res. 1996; 11: 1010-1018
- The epidemiology of peripheral fractures.Bone. 1996; 18: 209S-213S
- Incidence of colles' fracture in Uppsala. A prospective study of a quarter-million population.Acta Orthop Scand. 1992; 63: 213-215
- Osteoporotic fractures of the proximal humerus in elderly Finnish persons: Sharp increase in 1970–1998 and alarming projections for the new millennium.Acta Orthop Scand. 2000; 71: 465-470
- Osteoporosis: review of the evidence for prevention, diagnosis, and treatment and cost-effective analysis. Introduction. National Osteoprosis Foundation Osteoporosis Int Suppl, Washington, DC1998: S7-S80
- Are biochemical markers for bone turnover clinically useful for monitoring therapy in individual osteoporotic patients?.Bone. 2000; 26: 551-552
- Application of a new serum assay for type I collagen cross-linked n-telopeptides: Assessment of diurnal changes in bone turnover with and without alendronate treatment.Calcif Tissue Int. 1998; 63: 102-106
- Serum ctx: a new marker of bone resorption that shows treatment effect more often than other markers because of low coefficient of variability and large changes with bisphosphonate therapy.Calcif Tissue Int. 2000; 66: 100-103
- Estrogen replacement therapy and fractures in older women. Study of Osteoporotic Fractures research group.Ann Intern Med. 1995; 122: 9-16
- Risk factors for longitudinal bone loss in elderly men and women: The Framingham Osteoporosis Study.J Bone Miner Res. 2000; 15: 710-720
- Population-based study of survival after osteoporotic fractures.Am J Epidemiol. 1993; 137: 1001-1015
- Mortality after all major types of osteoporotic fracture in men and women: an observational study.Lancet. 1999; 353: 878-882
- Clinical outcomes and mortality after hip fracture: a 2-year follow-up study.Bone. 1996; 18: 149S-157S
- Contribution of vertebral deformities to chronic back pain and disability. The study of osteoporotic fractures research group.J Bone Miner Res. 1992; 7: 449-456
- The association of radiographically detected vertebral fractures with back pain and function: A prospective study.Ann Intern Med. 1998; 128: 793-800
- Late physical and functional effects of osteoporotic fracture in women: The Rancho Bernardo study.J Am Geriatr Soc. 1995; 43: 955-961
- The clinical consequences of vertebral compression fracture.Bone. 1992; 13: S27-S31
- A clinical profile of back pain and disability in patients with spinal osteoporosis.Bone. 1994; 15: 27-30
- Association of osteoporotic vertebral compression fractures with impaired functional status.Am J Med. 1993; 94: 595-601
- Vertebral fracture and other predictors of physical impairment and health care utilization.Arch Intern Med. 1996; 156: 2469-2475
- Prevalent vertebral deformities predict mortality and hospitalization in older women with low bone mass. Fracture Intervention Trial research group.J Am Geriatr Soc. 2000; 48: 241-249
- Vertebral fractures and mortality in older women: a prospective study. Study of Osteoporotic Fractures research group.Arch Intern Med. 1999; 159: 1215-1220
- The clinical impact of vertebral fractures: quality of life in women with osteoporosis.Bone. 1996; 18: 185S-189S
- Effects of high-intensity strength training on multiple risk factors for osteoporotic fractures. A randomized controlled trial.JAMA. 1994; 272: 1909-1914
- Impact of a 12-month exercise program on the physical and psychological health of osteopenic women.J Am Geriatr Soc. 1996; 44: 756-762
- Weight-training effects on bone mineral density in early postmenopausal women.J Bone Miner Res. 1992; 7: 179-185
- Systematic review of randomized trials of the effect of exercise on bone mass in pre- and postmenopausal women.Calcif Tissue Int. 2000; 67: 10-18
- Postmenopausal spinal osteoporosis: flexion versus extension exercises.Arch Phys Med Rehabil. 1984; 65: 593-596
- Low fractional calcium absorption increases the risk for hip fracture in women with low calcium intake. Study of Osteoporotic Fractures research group.Ann Intern Med. 2000; 132: 345-353
- A controlled trial of the effect of calcium supplementation on bone density in postmenopausal women.N Engl J Med. 1990; 323: 878-883
- Does calcium supplementation prevent postmenopausal bone loss? A double- blind, controlled clinical study.N Engl J Med. 1987; 316: 173-177
- Long-term effects of calcium supplementation on serum parathyroid hormone level, bone turnover, and bone loss in elderly women.J Bone Miner Res. 1998; 13: 168-174
- Correcting calcium nutritional deficiency prevents spine fractures in elderly women.J Bone Miner Res. 1996; 11: 1961-1966
- Calcium supplementation prevents seasonal bone loss and changes in biochemical markers of bone turnover in elderly New England women: a randomized placebo-controlled trial.J Clin Endocrinol Metab. 1998; 83: 3817-3825
- Annual injection of vitamin D and fractures of aged bones.Calcif Tissue Int. 1992; 51: 105-110
- Effect of vitamin D supplementation on wintertime and overall bone loss in healthy postmenopausal women.Ann Intern Med. 1991; 115: 505-512
- Vitamin D3 and calcium to prevent hip fractures in the elderly women.N Engl J Med. 1992; 327: 1637-1642
- Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older.N Engl J Med. 1997; 337: 670-676
- Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The alendronate phase III osteoporosis treatment study group.N Engl J Med. 1995; 333: 1437-1443
- Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. Phase III osteoporosis treatment study group.J Clin Endocrinol Metab. 2000; 85: 3109-3115
- Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial research group.Lancet. 1996; 348: 1535-1541
- Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial.JAMA. 1998; 280: 2077-2082
- Fracture risk reduction with alendronate in women with osteoporosis: The Fracture Intervention Trial. FIT research group.J Clin Endocrinol Metab. 2000; 85: 4118-4124
- Effect of alendronate on limited-activity days and bed-disability days caused by back pain in postmenopausal women with existing vertebral fractures. Fracture Intervention Trial research group.Arch Intern Med. 2000; 160: 77-85
- Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate once-weekly study group.Aging (Milano). 2000; 12: 1-12
- Dose-response relationships for alendronate treatment in osteoporotic elderly women. Alendronate elderly osteoporosis study centers.J Clin Endocrinol Metab. 1997; 82: 265-274
- An open-label extension study of alendronate treatment in elderly women with osteoporosis.Calcif Tissue Int. 1999; 64: 463-469
- Risedronate reverses bone loss in postmenopausal women with low bone mass: Results from a multinational, double-blind, placebo-controlled trial.J Clin Endocrinol Metab. 2000; 85: 1895-1900
- Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral efficacy with risedronate therapy (VERT) study group.JAMA. 1999; 282: 1344-1352
- Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral efficacy with risedronate therapy (VERT) study group.Osteoporos Int. 2000; 11: 83-91
- Effect of risedronate on the risk of hip fracture in elderly women. Hip intervention program study group.N Engl J Med. 2001; 344: 333-340
- Upper gastrointestinal toxicity of alendronate.Am J Gastroenterol. 2000; 95: 634-640
- Effects of alendronate on gastric and duodenal mucosa.Am J Gastroenterol. 1998; 93: 753-757
- Endoscopic comparison of esophageal and gastroduodenal effects of risedronate and alendronate in postmenopausal women.Gastroenterology. 2000; 119: 631-638
- Alendronate prevents postmenopausal bone loss in women without osteoporosis. A double-blind, randomized, controlled trial. Alendronate osteoporosis prevention study group.Ann Intern Med. 1998; 128: 253-261
- Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early postmenopausal intervention cohort study group.N Engl J Med. 1998; 338: 485-492
- Alendronate and estrogen-progestin in the long-term prevention of bone loss: Four-year results from the early postmenopausal intervention cohort study. A randomized, controlled trial.Ann Intern Med. 1999; 131: 935-942
- Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The postmenopausal estrogen/progestin interventions (PEPI) trial.JAMA. 1995; 273: 199-208
- The minimum effective dose of estrogen for prevention of postmenopausal bone loss.Obstet Gynecol. 1984; 63: 759-763
- The effect of low-dose continuous estrogen and progesterone therapy with calcium and vitamin d on bone in elderly women. A randomized, controlled trial.Ann Intern Med. 1999; 130: 897-904
- Prevention of femoral and lumbar bone loss with hormone replacement therapy and vitamin D3 in early postmenopausal women: a population- based 5-year randomized trial.J Clin Endocrinol Metab. 1999; 84: 546-552
- Bone mineral density response to estrogen replacement in frail elderly women: a randomized controlled trial.JAMA. 2001; 286: 815-820
- Treatment of postmenopausal osteoporosis with transdermal estrogen.Ann Intern Med. 1992; 117: 1-9
- Prevention of spinal osteoporosis in oophorectomised women.Lancet. 1980; 2: 1151-1154
- Estrogen replacement therapy i: a 10-year prospective study in the relationship to osteoporosis.Obstet Gynecol. 1979; 53: 277-281
- Evidence for efficacy of drugs affecting bone metabolism in preventing hip fracture.Br Med J. 1992; 305: 1124-1128
- Hormone replacement therapy and risk of hip fracture: population based case-control study. The Swedish Hip Fracture Study group.Br Med J. 1998; 316: 1858-1863
- Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) research group.JAMA. 1998; 280: 605-613
- Osteoporosis prevention and treatment with sex hormone replacement therapy.Clin Rheum. 1995; 14: 14-17
- Hormone replacement therapy and prevention of non-vertebral fractures: a meta-analysis of randomized trials.JAMA. 2001; 285: 2891-2897
- Timing of postmenopausal estrogen for optimal bone mineral density. The Rancho Bernardo study.JAMA. 1997; 277: 543-547
- Do estrogens improve bone mineral density in osteoporotic women aver age 65 years?.J Bone Miner Res. 1992; 7: 1275
- The effect of postmenopausal estrogen therapy on bone density in elderly women.N Engl J Med. 1993; 329: 1141-1146
- Variation in the efficacy of hormone replacement therapy in the prevention of hip fracture. Swedish Hip Fracture study group.Osteoporos Int. 1998; 8: 540-546
- Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women.N Engl J Med. 1997; 337: 1641-1647
- Treatment of postmenopausal women with osteoporosis or low bone density with raloxifene. Raloxifene study group.Osteoporos Int. 1999; 10: 330-336
- Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) investigators.JAMA. 1999; 282: 637-645
- Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study.BMJ. 1992; 305: 556-561
- Comparison of alendronate and intranasal calcitonin for treatment of osteoporosis in postmenopausal women.J Clin Endocrinol Metab. 2000; 85: 1783-1788
- Intranasal salmon calcitonin for the prevention and treatment of postmenopausal osteoporosis.Calcif Tissue Int. 1996; 59: 6-11
- Effect of salcatonin given intranasally on early postmenopausal bone loss.BMJ. 1989; 299: 477-479
- A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the Prevent Recurrence of Osteoporotic Fractures study. PROOF study group.Am J Med. 2000; 109: 267-276
- What PROOF proves about calcitonin and clinical trials.Am J Med. 2000; 109: 330-331
- Phytoestrogens and bone.Baillieres Clin Endocrinol Metab. 1998; 12: 543-557
- Ipriflavone in the treatment of postmenopausal osteoporosis: A randomized controlled trial.JAMA. 2001; 285: 1482-1488
- Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers.J Clin Endocrinol Metab. 2000; 85: 3069-3076
- Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate.J Clin Endocrinol Metab. 2000; 85: 2129-2134
- Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis.N Engl J Med. 2001; 344: 1434-1441
- Alendronate and estrogen effects in postmenopausal women with low bone mineral density. Alendronate/estrogen study group.J Clin Endocrinol Metab. 2000; 85: 720-726
- A four-year randomized controlled trial of hormone replacement and bisphosphonate, alone or in combination, in women with postmenopausal osteoporosis.Am J Med. 1998; 104: 219-226
- Addition of alendronate to ongoing hormone replacement therapy in the treatment of osteoporosis: a randomized, controlled clinical trial.J Clin Endocrinol Metab. 1999; 84: 3076-3081
- Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis.Lancet. 1997; 350: 550-555
- Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal.J Bone Miner Res. 2001; 16: 925-931
- Risk fractures for osteoporotic fractures in elderly men.Am J Epidemiol. 1996; 144: 255
- Low levels of estradiol are associated with vertebral fractures in older men, but not women: The Rancho Bernardo study.J Clin Endocrinol Metab. 2000; 85: 219-223
- Association of hypogonadism and estradiol levels with bone mineral density in elderly men from the Framingham study.Ann Intern Med. 2000; 133: 951-963
- Lack of association between free testosterone and bone density separate from age in elderly males.Calcif Tissue Int. 1993; 52: 67-69
- Marked decline in trabecular bone mineral content in healthy men with age: Lack of association with sex steroid levels.J Am Geriatr Soc. 1987; 35: 189-197
- Bone mineral density and androgen levels in elderly males.Calcif Tissue Int. 1999; 65: 417-421
- Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: a key role for bioavailable estrogen.J Clin Endocrinol Metab. 1998; 83: 2266-2274
- Osteoporosis in men.Baillieres Clin Rheumatol. 1997; 11: 613-629
- Alendronate for the treatment of osteoporosis in men.N Engl J Med. 2000; 343: 604-610
- Therapeutic role of androgens in the treatment of osteoporosis in men.Baillieres Clin Endocrinol Metab. 1998; 12: 453-470
- Osteoporosis in men.Rheum Dis Clin North Am. 2001; 27: 19-47
- Hip fractures in Finland between 1970 and 1997 and predictions for the future.Lancet. 1999; 353: 802-805
- Clinical use of biochemical markers of bone remodeling: Current status and future directions.Osteoporos Int. 2000; 11: 467-480
- Risk factors for osteoporotic fractures in elderly men.Am J Epidemiol. 1996; 144: 255-263
- Osteoporosis in men.Endocrinol Metab Clin North Am. 1998; 27: 349-367
Article info
Identification
Copyright
© 2002 Elsevier Science (USA). Published by Elsevier Inc. All rights reserved.
